Assessing the Impact of Screening Colonoscopy on Mortality in the Medicare Population
Some have recommended against routine screening for colorectal cancer (CRC) among patients ≥75 years of age, while others have suggested that screening colonoscopy (SC) is less beneficial for women than men. We estimated the expected benefits (decreased mortality from CRC) and harms (SC-related mortality) of SC based on sex, age, and comorbidity.
To stratify older patients according to expected benefits and harms of SC based on sex, age, and comorbidity.
Retrospective study using Medicare claims data.
Medicare beneficiaries 67–94 years old with and without CRC.
Life expectancy, CRC- and colonoscopy-attributable mortality rates across strata of sex, age, and comorbidity, pay-off time (i.e. the minimum time until benefits from SC exceeded harms), and life-years saved for every 100,000 SC.
Increasing age and comorbidity were associated with lower CRC-attributable mortality. Due to shorter life expectancy and CRC-attributable mortality, the benefits associated with SC were substantially lower among patients with greater comorbidity. Among men aged 75–79 years with no comorbidity, the number of life-years saved was 459 per 100,000 SC, while men aged 67–69 with ≥3 comorbidities had 81 life-years saved per 100,000 SC. There was no evidence that SC was less effective in women. Among men and women 75–79 with no comorbidity, number of life-years saved was 459 and 509 per 100,000 SC, respectively; among patients with ≥3 comorbidities, there was no benefit for either men or women.
Although the effectiveness of SC was equivalent for men and women, there was substantial variation in SC effectiveness within age groups, arguing against screening recommendations based solely on age.
Key Wordsscreening colonoscopy colorectal cancer screening medicare
- 1.Force USPST. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(9):627–37.Google Scholar
- 5.(CDC) CfDCaP. Behavioral Risk Factor Surveillance System Survey Data. Vol. 2009. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009.Google Scholar
- 17.Fox E, Landrum-McNiff K, Zhong Z, Dawson NV, Wu AW, Lynn J. Evaluation of prognostic criteria for determining hospice eligibility in patients with advanced lung, heart, or liver disease. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. JAMA. 1999;282(17):1638–45.PubMedCrossRefGoogle Scholar
- 19.Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 Suppl):IV-55–61.Google Scholar
- 20.Warren J, Klabunde C, Schrag D, Bach P, Riley G. Overview of SEER-Medicare data: content, research applictions, and generalizability to the United States elderly population. Medical Care. 2002;40(supp):IV-3–IV-18.Google Scholar
- 32.SEER Cancer Statistics Review: 1973–1993. In: Institute NC, ed. Vol. 2009. Bethesda, MD.Google Scholar
- 49.Baxter NN, Rabeneck L. Is the effectiveness of colonoscopy "good enough" for population-based screening? J Natl Cancer Inst;102(2):70–1.Google Scholar
- 51.Singh H, Nugent Z, Demers AA, Kliewer EV, Mahmud SM, Bernstein CN. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology;139(4):1128–37.Google Scholar